Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Account Payables (2018 - 2025)

X4 Pharmaceuticals' Change in Account Payables history spans 8 years, with the latest figure at $642000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 723.08% year-over-year to $642000.0; the TTM value through Dec 2025 reached -$3.0 million, down 941.61%, while the annual FY2025 figure was -$3.0 million, 941.61% down from the prior year.
  • Change in Account Payables reached $642000.0 in Q4 2025 per XFOR's latest filing, up from -$2.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.9 million in Q4 2022 to a low of -$3.4 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $128000.0, with a median of $41000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: crashed 3000.0% in 2022, then skyrocketed 61800.0% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $1.9 million in 2021, then skyrocketed by 109.89% to $3.9 million in 2022, then plummeted by 79.31% to $808000.0 in 2023, then tumbled by 90.35% to $78000.0 in 2024, then surged by 723.08% to $642000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Change in Account Payables are $642000.0 (Q4 2025), -$2.7 million (Q3 2025), and -$3.4 million (Q2 2025).